By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galera Therapeutics, LLC 

St. Louis  Missouri    U.S.A.
Phone: n/a Fax: n/a



Company News
Galera Announces Promising Innovative Medicines Designation From The United Kingdom’s Medicines And Healthcare Products Regulatory Agency For GC4419 For The Reduction Of Oral Mucositis In Head And Neck Cancer Patients 7/31/2017 11:50:27 AM
Galera Completes Enrollment In Phase IIb Clinical Trial With Lead Compound GC4419 For Treatment Of Oral Mucositis 6/15/2017 7:49:45 AM
Galera Expands Series B to $57 Million 11/28/2016 8:11:36 AM
Galera Announces Presentation Of One-Year Follow-up Data From A Phase 1b/2a Study Of GC4419 In The Reduction Of Severe Oral Mucositis 9/28/2016 12:13:23 PM
ASCO2016: Galera Announces Presentation At ASCO Of Positive Results From Study Of GC4419 For The Reduction Of Severe Oral Mucositis 6/6/2016 8:15:54 AM
Galera Ups Series B Financing to $42 Million 2/3/2016 6:34:13 AM
Galera Announces Fast Track Designation Of GC4419 For Prevention Of Oral Mucositis 1/7/2016 10:54:11 AM
Galera Raises $37 Million in Series B Financing 10/14/2015 9:38:27 AM
Galera Therapeutics, LLC Raises $11 Million in Series A Financing 12/11/2012 7:54:26 AM
Galera Therapeutics, LLC Secures Funding for New Cancer Treatment 6/15/2010 10:35:26 AM